HIGHLIGHTS
- who: Yasuyuki Okuda from the Data Intelligence Department, Daiichi Sankyo Co [, ]Ltd, Tokyo, Japan have published the research: The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial, in the Journal: (JOURNAL)
- how: The authors investigated the mechanism of the effect of an MR blocker on reducing the urinary albumin-to-creatinine ratio (UACR) using data from a randomized double-blind placebo-controlled phase 3 study (ESAX-DN) of a new nonsteroidal MR blocker esaxerenone. There was some variability in the proportion of the mediated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.